Expression of brain-derived neurotrophic factors, neurotrophin-3, and neurotrophin-4 in the nucleus accumbens during heroin dependency and withdrawal

Yixin Li, Baijuan Xia, Rongrong Li, Dan Yin, Yanlin Wang and Wenmei Liang

Neurotrophins, brain-derived neurotrophic factors (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4), have been implicated in the modulation of heroin dependency. This study was designed to explore the expression alterations of BDNF, NT-3, and NT-4 in the context of heroin dependence and withdrawal in the rat nucleus accumbens (NAc). Heroin dependence was induced by a progressive intraperitoneal treatment of heroin. The results showed that the expression levels of BDNF and NT-4 were significantly decreased in the NAc of rats with heroin addiction in comparison with the control group, whereas there was a significant increase in BDNF and NT-4 expressions in the groups of rats with both naloxone-induced and spontaneous withdrawal. Moreover, NT-3 expression was markedly increased in the NAc of rats with heroin addiction and spontaneous withdrawal in comparison with the control group, but decreased in the NAc of rats with naloxone-induced withdrawal. These results indicated that chronic administration of heroin results in the alterations of BDNF, NT-3, and NT-4 expressions in the rat NAc. BDNF, NT-3, and NT-4 may play a critical role in the development of heroin dependency and withdrawal. NeuroReport 28:654–660 Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc.

NeuroReport 2017, 28:654–660

Keywords: brain-derived neurotrophic factor, heroin dependence, heroin withdrawal, neurotrophin-3, neurotrophin-4, nucleus accumbens, rat

Department of Histology and Embryology, Guizhou Medical University, Guiyang, China

Correspondence to Wenmei Liang, MD, Department of Histology and Embryology, Guizhou Medical University, Guiyang 550025, China
Tel/fax: + 86 851 869 08567; e-mail: wenmeiliang1@163.com

Received 7 April 2017 accepted 26 April 2017

Introduction

Heroin dependence is a chronically relapsing brain disease characterized by a compulsion to take heroin with an inability to limit the drug intake, continuous demand for heroin, tolerance (i.e. craving for larger doses), and painful withdrawal [1,2]. This disorder is a global healthcare burden and contributes toward serious behavioral, medical, psychiatric, and social consequences [3]. In response to continued opiate administration, several long-term structural and biochemical alterations occur in the brain that can be explained collectively as neuroplasticity or neuroadaptations [4]. The functional brain impairment caused by long-term opioid use might intensify dependence and contribute toward a relapse [5]. Although the underlying pathogenesis of heroin addiction remains poorly understood, recent studies have shown that neurotrophins play an important role in the development of heroin dependency and withdrawal.

The family of neurotrophins including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4) are important regulators of neural survival, development, function, and plasticity [6,7]. BDNF is a critical neurotrophic factor involved in cell growth, survival, and differentiation by regulating synaptic plasticity and neurogenesis [8]. Studies of acute exposure to cocaine have shown an increased expression of BDNF in the prefrontal cortex, ventral tegmental area (VTA), striatum, and nucleus accumbens (NAc) [4,9]. Grimm et al. [10] reported that a time-dependent increase in BDNF expression was observed within the mesolimbic dopamine system up to 90 days after withdrawal from cocaine. However, chronic morphine administered to mice decreased BDNF expression in the VTA [11]. In addition, clinical studies have shown contradictory results of BDNF, with the serum levels being increased and decreased in heroin addicts [12–14]. Also, it is documented that NT-3 contributes toward the initiation of behavioral sensitization to cocaine and modulates noradrenergic neuron function and opiate withdrawal [15,16]. NT-4 has been shown to be required for tolerance to morphine in the mouse [17]. Overall, these studies indicate that changes in neurotrophic factors BDNF, NT-3, and NT-4 may be involved in the pathophysiology of opiate addiction.

The NAc, a basal forebrain structure receiving glutamatergic inputs from the prefrontal cortex, the amygdale, and VTA, is a critical component of the mesocorticolimbic system, a brain circuitry involved in reward and...
motivation and it has been the target of addictive drugs [18]. Considerable evidence supports the involvement of dopaminergic neurons in the VTA and their projections to the VTA or NAc in drug-induced rewarding properties [18,19]. Besides glutamate and dopamine, recent studies have shown that administration of exogenous neurotrophic factors in the NAc increased the frequency of behaviors related to addiction and relapse; conversely, a decrease in neurotrophic factors is linked to opposite behaviors [9,20]. However, the response of endogenous neurotrophins in the NAc to heroin treatment remains elusive. In the present study, we sought to investigate the expression of BDNF, NT-3, and NT-4 in the rat NAc during heroin dependency and withdrawal to further understand the roles of neurotrophins in the development of heroin dependence and withdrawal and explore the potential treatment for the prevention and management of heroin addiction.

Materials and methods

Animals
In all, 32 male Sprague–Dawley rats weighing 180–220 g (Experimental Animal Center of Guizhou Medical University) were divided randomly into four groups: heroin-dependent group, spontaneous withdrawal group, naloxone-induced withdrawal group, and saline control group. Rats were housed three per cage under a 12 h light/dark cycle (light: 8:00–20:00) in a room with controlled temperature (22±2°C), humidity (50±10%), and free access to water and food. Rats were individually tested in the procedure room adjacent to the animal room. All animal protocols and experimental procedures were approved by the Ethics Committee of Guizhou Medical University Drug Administration. The study was carried out in the Animal Laboratory of Guizhou Medical University, Guiyang, China, between May 2015 and February 2016.

Heroin dependence and withdrawal
For repeated heroin or saline treatment, Sprague–Dawley rats were administered intraperitoneal injections of either saline (0.9% NaCl, 1 ml/kg) or heroin (provided by Police Bureau of Guizhou Province, China, containing 92.09% of diacetylmorphine, 7.91% of acetylmorphine) for 9 days. Heroin was dissolved in a 0.9% NaCl solution immediately before injection. In the heroin-dependent group, the spontaneous withdrawal group, and the naloxone-induced withdrawal group, rats were subcutaneously injected with heroin twice a day for 9 days. The dose for each injection was 3 mg/kg on day 1, and was increased by 3 mg/kg each day. On day 9, the dose was 27 mg/kg. This pattern of heroin administration has been shown to induce physiological dependence in rats [21]. Rats in the control group were administered saline treatment with the same procedure.

After the last injection of heroin on day 9, rats in the spontaneous withdrawal group were observed for withdrawal symptoms on day 10. In the naloxone-induced withdrawal group, heroin withdrawal symptoms were precipitated by the administration of naloxone (5 mg/kg, intraperitoneally) on day 10. Symptoms of withdrawal were scored for 30 min.

Behavioral observations
Behavioral observations were carried out as described previously [21]. In rats with heroin administration, behaviors were recorded during visual checks for 2 h, starting after the first daily injection. Typical heroin-induced behaviors including explore, rear walk, hyperactivity, straggling, erecting, licking the hair, eat/drink, and biting paws were recorded for each rat. Five behavioral characteristics of the rat heroin abstinence syndrome including writhing, jumping, wet-dog shakes, teeth chatting, and rearing were recorded and scored after an intraperitoneal injection of naloxone and lasted for 30 min. At the end of the rating period, the amount of body weight loss was measured and scored as described previously [22]. The individual who measured behavior was blinded to the experimental groups.

Sample preparation
In the heroin-dependent group and the control group, brains were extracted after the last injection of heroin or saline. In the spontaneous withdrawal group, rats received the same chronic treatment as the heroin-dependent group, and brains were extracted 7 days after the last injection of heroin. In the naloxone-induced withdrawal group, brains were extracted 30 min after the injection of naloxone. Rats were deeply anesthetized with sodium pentobarbital (80 mg/kg, intraperitoneally) and perfused with PBS and a 4% paraformaldehyde solution sequentially from the left ventricle. The paraffin-embedded brain tissue was horizontally sliced at a thickness of 10 μm sections and then detected with immunohistochemical staining. The NAc was punched with a 14 G needle, and then stored in liquid nitrogen until they were determined by western blotting.

Immunohistochemical staining
To localize the expression of BDNF, NT-3, and NT-4, immunohistochemistry staining was performed. First, sections were rinsed with PBS (3×5 min), treated with 0.5% H2O2 in PBS for 10 min, and then rinsed again in PBS (3×10 min). Then, sections were placed in a blocking solution containing 5% normal goat serum for 1 h, and then incubated with the primary antibodies to BDNF, NT-3, and NT-4 (diluted 1:500; Santa Cruz Biotechnology, Santa Cruz, Texas, USA) overnight at 4°C. A negative control without a primary antibody was performed. On the second day, tissue sections were rinsed in PBS and then incubated for 1 h at room temperature with the secondary antibodies (diluted 1:1000; Jackson ImmunoResearch Inc., West Grove, Pennsylvania, USA). The optical densities of positive staining were determined using Image Pro-Plus software.
NeuroReport 2017, Vol 28 No 11

Wet-dog shakes 23 ± 3*, # 12 ± 2*, #
Teeth chatting 12 ± 1*, #
Writhing 11 ± 2*, #
Rearing 15 ± 1*, #

Withdrawal syndrome test. Heroin caused a decrease in body weight. Rats were checked daily for body weight for 10 days. Both heroin-treated rats in the spontaneous withdrawal group (209 ± 3 g) and the naloxone-induced withdrawal group (183 ± 3 g) weighed significantly less than the vehicle-treated controls (217 ± 1 g) (*P < 0.05).

Alterations of NT-3 expression in the rat NAc during heroin dependence and withdrawal
Figure 3a-d shows that NT-3 expression was found to be mainly located in the cytoplasm in the rat NAc. After injection of heroin for 9 days, the NT-3 expression levels changed in the rat NAc in response to chronic heroin treatment. After injection of heroin for 9 days, the expression levels of BDNF were markedly decreased in the NAc of rats with heroin addiction in comparison with control rats (mean optical density: 0.295 ± 0.075 vs. 0.366 ± 0.099, P < 0.05) (Fig. 2e), whereas there was a significant increase in BDNF expressions in the groups of rats with naloxone-induced and spontaneous withdrawal (mean optical density: 0.521 ± 0.066 vs. 0.442 ± 0.049 vs. 0.566 ± 0.099, P < 0.05) (Fig. 2e). The heroin-induced changes in BDNF expression were represented by changes in the mean optical density in the NAc investigated. Western blotting was performed to further confirm the similar changes in BDNF expression in the rat NAc during heroin dependence and withdrawal (BDNF/β-actin: 0.57 ± 0.08 vs. 1.4 ± 0.1 vs. 1.27 ± 0.15 vs. 1.0 ± 0.0, P < 0.05) (Fig. 2f).

Results
Test of dependence on heroin
Both heroin-treated rats in the spontaneous withdrawal group and the naloxone-induced withdrawal group had higher numbers of wet-dog shakes, writhing, and rearing compared with the vehicle-treated controls (P < 0.05) (Table 1). In addition, naloxone precipitated a significant increase in jumping and teeth chatter (P < 0.05) (Table 1). Heroin caused a decrease in body weight. Rats were checked daily for body weight for 10 days. Both heroin-treated rats in the spontaneous withdrawal group (209 ± 3 g) and the naloxone-induced withdrawal group (183 ± 3 g) had significant less weight than the vehicle-treated controls (217 ± 1 g) (P < 0.05) (Fig. 1).

Alterations of BDNF expression in the rat NAc during heroin dependence and withdrawal
As shown in Fig. 2a-d, BDNF expression was found to be mainly located in the cytoplasm in the rat NAc. The BDNF expression levels changed in the rat NAc in response to chronic heroin treatment. After injection of heroin for 9 days, the expression levels of BDNF were markedly decreased in the NAc of rats with heroin addiction in comparison with control rats (mean optical density: 0.295 ± 0.075 vs. 0.366 ± 0.099, P < 0.05) (Fig. 2e), whereas there was a significant increase in BDNF expressions in the groups of rats with naloxone-induced and spontaneous withdrawal (mean optical density: 0.521 ± 0.066 vs. 0.442 ± 0.049 vs. 0.566 ± 0.099, P < 0.05) (Fig. 2e). The heroin-induced changes in BDNF expression were represented by changes in the mean optical density in the NAc investigated. Western blotting was performed to further confirm the similar changes in BDNF expression in the rat NAc during heroin dependence and withdrawal (BDNF/β-actin: 0.57 ± 0.08 vs. 1.4 ± 0.1 vs. 1.27 ± 0.15 vs. 1.0 ± 0.0, P < 0.05) (Fig. 2f).
Alterations of NT-4 expression in the rat NAc during heroin dependence and withdrawal

As shown in Fig. 4a–d, NT-4 expression was found to be mainly located in the cytoplasm in the rat NAc. Chronic heroin treatment altered the expression of NT-4 in the rat NAc. The levels of NT-4 expression were markedly decreased in the NAc of rats with heroin addiction in comparison with the control group (mean optical density: 0.312 ± 0.035 vs. 0.366 ± 0.099, *P < 0.05), whereas there was a significant increase in NT-4 expressions in the groups of rats with naloxone-induced and spontaneous withdrawal (mean optical density: 0.521 ± 0.066 vs. 0.442 ± 0.049 vs. 0.366 ± 0.099, *P < 0.05). Western blotting further confirmed the similar changes in NT-4 expression in the rat NAc during heroin dependence and withdrawal (NT-4/β-actin: 0.58 ± 0.09 vs. 1.37 ± 0.13 vs. 1.24 ± 0.03 vs. 1.0 ± 0.0, *P < 0.05) (Fig. 4c).

Discussions

The results of the present study show that chronic heroin administration and withdrawal differentially regulate the expression of neurotrophins BDNF, NT-3, and NT-4 in the rat NAc. Chronic heroin treatment led to a significant decrease in the expression levels of BDNF and NT-4 in the NAc of rats in comparison with the control group, whereas there was a significant increase in BDNF and NT-4 expression in the groups of rats during heroin withdrawal. In contrast to BDNF and NT-4, chronic heroin administration significantly increased NT-3 expression in the NAc of rats with heroin addiction and spontaneous withdrawal, but decreased in the NAc of rats with naloxone-induced withdrawal. These results support the notion that neurotrophins might play a critical role in opiate addiction and withdrawal.

The neurotrophins, a family of structurally and functionally related polypeptides, have been implicated in the maintenance of neuronal excitability and synaptic transmission, synaptic plasticity, neuroprotection, and drug addiction [24,25]. The four neurotrophins produce their biological effects by activating three paralogous receptor tyrosine kinases (TrkA, TrkB, and TrkC) and the 75 kDa a neurotrophin receptor (p75<sup>NTR</sup>) [26]. BDNF and NT-4 are selective for TrkB, whereas NT-3...
preferentially binds TrkA and TrkC receptors [22]. Neurotrophins have been associated with the addictive process, mostly regulating the dopaminergic transmission in the NAc, which receives projections from the VTA [19]. Intrainfusion of exogenous neurotrophic factors directly into the VTA or NAc has been shown to prevent some of the biochemical and structural adaptations to chronic drug exposure [6,27,28]. However, the effect of heroin on the expression of endogenous BDNF, NT-3, and NT-4 in the rat NAc has not yet been well elucidated.

BDNF is best characterized for its role in promoting the neural and behavioral plasticity induced by cocaine or other stimulants through a key reward circuit where BDNF is engaged in a feed-forward loop that promotes further actions of stimulant drugs [29,30]. It has been shown previously that exogenously added BDNF and NT-4 can produce similar effects in the NAc [6]. In the present study, the expression levels of BDNF and NT-4 were significantly decreased in the NAc of rats with heroin addiction in comparison with the control group. Our result is consistent with previous studies that showed that chronic morphine administration decreases BDNF expression in the NAc [31,32]. BDNF in the NAc is predominantly supplied by anterograde axonal transport from cortical pyramidal neurons in PFA, with a minor contribution from dopamine neurons in VTA [33]. Therefore, a possible speculation of the decrease in BDNF expression observed was because of the decrease in protein synthesis, anterograde axonal transport from PFA and VTA, where decreased BDNF expression was induced by chronic cocaine and morphine exposure [11,34]. BDNF expression in the NAc in response to different stimulants, however, is not uniform. Several studies have found increased BDNF expression in the NAc [9,35]. In addition, Smith et al. [17] reported mice lacking NT-4 reduces tolerance to morphine. Thus, the endogenous expression of BDNF and NT-4 to opiates may depend not only on the particular drug type or drug regimen used but also on the presence of other factors that are not yet defined.

In our results, increases in BDNF and NT-4 expressions were found in the groups of rats with both naloxone-induced and spontaneous withdrawal compared with the control group. These results are in agreement with previous observations showing a time-dependent increase in
BDNF expression in the NAc after withdrawal from prolonged cocaine self-administration [10,35]. In addition, increased serum/plasma BDNF levels were found in heroin-dependent patients during withdrawal [14]. It has been hypothesized that BDNF and NT-4 may be responsible for maintenance of the neuronal phenotype [6]. The increases in BDNF and NT-4 expressions could serve to counter the neurotoxicity caused by chronic heroin withdrawal on the biochemistry of NAc neurons. Future studies with antagonists to BDNF and NT-4 will be needed to examine the exact effects of chronic heroin withdrawal.

In contrast to the alterations in BDNF and NT-4 following heroin dependence and withdrawal, there was a significant increase in NT-3 expression in the NAc of rats with heroin addiction and spontaneous withdrawal, but decrease in the NAc of rats with naloxone-induced withdrawal. Our results are similar to earlier studies in which the effects of different stimulants on NT-3 in the different brain regions were assessed. For example, Pierce et al. [15] reported that an acute injection of cocaine resulted in a marked increase in NT-3 expression in the VTA, which would be expected to increase BDNF signaling from the VTA to the NAc. Hatami et al. [22] reported that chronic morphine treatment and withdrawal induced a significant upregulation of NT-3 expression in paragigan to cellularis. In addition, a significant increase in NT-3 expression in the hippocampus was found following chronic exposure to ethanol [36]. Increased NT-3 may function as a trophic factor for many neurotrophin-responsive neuronal populations. Our results indicate that increased expression of NT-3 in the NAc during heroin treatment and spontaneous withdrawal could then contribute toward adaptations and homeostatic mechanisms that occur in the NAc as well.

**Conclusion**

Our investigation showed the differential regulation of BDNF, NT-3, and NT-4 in the rat NAc following heroin dependency and withdrawal. These findings provide further evidence for the involvement of neurotrophins particularly in the NAc in the development of heroin dependence and withdrawal. Although the exact physiological role played by these neurotrophin alterations during the course of heroin treatment and withdrawal will require further investigation, these results may highlight
a potential influence of neurotrophic factors in heroin addiction.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 81260207), The Foundation of Guizhou Educational Committee No. [2011]28, [2014] 268, and the United Foundation Project of Guiyang Science and Technology Bureau (No. 2016001-6).

Conflicts interest

There are no conflicts of interest.

References

1 McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284(16):1689–1695.

2 Ghita UE, Zhai H, Wu P, Ariaavara M, Shaham Y, Lu L. Role of BDNF and GDNF in drug reward and relapse: a review. Neurosci Biobehav Rev 2010; 34:157–171.

3 Haerian BS. BDNF rs86265 polymorphism and drug addiction: a systematic review and meta-analysis. Pharmacogenomics; 14:2055–2065.

4 McCarthy DM, Brown AN, Bhide PG. Regulation of BDNF expression by cocaine. Yale J Biol Med 2012; 85:437–446.

5 Cadet JL, Bisagno V, Mitroy CM. Neuropathology of substance use disorders. Acta Neuropathol 2014; 127:91–107.

6 Berhow MT, Russell DS, Terwilliger RZ, Beitner-Johnson D, Self DW, Lindsay RM, et al. Influence of neurotrophic factors on morphine- and cocaine-induced biochemical changes in the mesolimbic dopaminergic system. Neuroscience 1995; 68:969–978.

7 Lhuillier AG, Moreira FP, da Silva RA, Marques MB, Bittencourt G, Pinheiro RT, et al. Increased serum neurotrophin levels related to alcohol use disorder in a young population sample. Alcohol Clin Exp Res 2015; 39:30–33.

8 Costa MA, Giraud M, Dalmau F, Malauzat D. Brain-derived neurotrophic factor serum levels in alcohol-dependent subjects 6 months after alcohol withdrawal. Alcohol Clin Exp Res 2011; 35:1965–1973.

9 Graham DL, Edwards S, Bachtell RK, DiLeone RJ, Rios M, Self DW. Dynamic BDNF activity in nucleus accumbens with cocaine use increases self-rewarding effects. Front Psychiatry; 20:820–825.

10 Grimm JW, Lu L, Hayashi T, Hope BT, Su TP, Shaham Y. Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopaminergic system after withdrawal from cocaine: implications for incubation of cocaine craving. J Neurosci 2003; 23:742–747.

11 Chu NN, Zuo YF, Meng L, Lee DY, Han JS, Cui CL. Peripheral electrical stimulation reversed the cell size reduction and increased BDNF level in the ventral tegmental area in chronic morphine-treated rats. Brain Res 2007; 1193:90–98.

12 Angelucci F, Ricci V, Pompom M, Conte G, Mathe AA, Attilio Tonali P, et al. Chronic heroin and cocaine abuse is associated with decreased serum concentrations of the nerve growth factor and brain-derived neurotrophic factor. J Psychopharmacol 2007; 21:820–825.

13 Heberlein A, Dursteler-MacFauland KM, Lenz B, Freling H, Grosse M, Bonsch D, et al. Serum levels of BDNF are associated with craving in opiate-dependent patients. J Psychopharmacol 2011; 25:1480–1484.

14 Zhang J, Zhang X, Su H, Tao J, Xie Y, Han B, et al. Increased serum brain-derived neurotrophic factor levels during opiate withdrawal. Neurosci Lett 2014; 571:61–65.

15 Pierce RG, Pierce-Bancroft AF, Prasad BM. Neurotrophin-3 contributes to the initiation of behavioral sensitization to cocaine by activating the Ras/Mitogen-activated protein kinase signal transduction cascade. J Neurosci 1999; 19:8685–8695.

16 Akbarian S, Bates B, Liu RJ, Skirboll SL, Pejchal T, Coppola V, et al. Neurotrophin-3 modulates noradrenergic neuron function and opiate withdrawal. Mol Psychiatry 2001; 6:593–604.

17 Smith DJ, Lei TL, Liu X. Neurotrophin-4 is required for tolerance to morphine in the mouse. Neurosci Lett 2003; 340:103–106.

18 Quintero GC. Role of nucleus accumbens glutamatergic plasticity in drug addiction. Neuropsychiatr Dis Treat 2013; 9:1499–1512.

19 Bolanos CA, Nestler EJ. Neurotrophic mechanisms in drug addiction. Neuromolecular Med 2004; 5:69–83.

20 Hall FS, Sora I, Droganou J, Li XF, Geoo M, Uhl GR. Molecular mechanisms underlying the rewarding effects of cocaine. Ann N Y Acad Sci 2004; 1025:47–56.

21 Seip KM, Reed B, Ho A, Kreek MJ. Measuring the incentive value of escalating doses of heroin in heroin-dependent Fischer rats during acute spontaneous withdrawal. Psychopharmacology (Berl) 2012; 218:59–72.

22 Hatami H, Oryan S, Semnann S, Kazemi B, Bandepour M, Ahmadiani A. Alterations of BDNF and NT-3 genes expression in the nucleus paragigantocellularis during morphine dependence and withdrawal. Neuroporphysiology 2007; 41:321–328.

23 Paxinos G, Watson CR, Emson PC. AChE-stained horizontal sections of the rat brain in stereotaxic coordinates. J Neurosci Methods 1980; 3:129–149.

24 Numans S, Lane-Ladd SB, Zhang L, Lundgren KH, Russell DS, Serrovy KB, et al. Differential regulation of neurotrophin and trk receptor mRNAs in catecholaminergic nuclei during chronic opiate treatment and withdrawal. J Neurosci 1998; 18:10700–10708.

25 Nestler EJ. Common molecular and cellular substrates of addiction and memory. Neurobiol Learn Mem 2002; 78:637–647.

26 Bothwell M. Recent advances in understanding neurotrophin signaling. F1000Res 2016; 5:F1000.

27 Sklar-Tavron L, Shi WX, Lane SB, Harris HW, Bunney BS, Nestler EJ. Chronic morphine induces visible changes in the morphology of mesolimbic dopamine neurons. Proc Natl Acad Sci USA 1996; 93:11202–11207.

28 Horger BA, Iyasere CA, Berhow MT, Messer CJ, Nestler EJ, Taylor JR. Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. J Neurosci 1999; 19:4110–4122.

29 Lobo MK, Covington HE 3rd, Chaudhury D, Friedman AK, Sun H, Damez-Werno D, et al. Cell type-specific loss of BDNF signaling mimics optogenetic control of cocaine reward. Science 2010; 330:385–390.

30 Vargas-Perez H, Bahi A, Bufalino MR, Ting AKR, Maal-Bared G, Lam J, et al. BDNF signaling in the VTA links the drug-dependent state to drug withdrawal aversions. J Neurosci 2014; 34:7898–7909.

31 Koo JW, Mazev-Robinson MS, Chaudhury D, Juarez B, LaPlant Q, Ferguson D, et al. BDNF is a negative modulator of morphine action. Science 2012; 338:124–128.

32 Koo JW, Lobo MK, Chaudhury D, Labonte B, Friedman A, Heller E, et al. Loss of BDNF signaling in D1R-expressing neurons enhances morphine reward by reducing GABA inhibition. Neuropsychopharmacology 2014; 39:2646–2653.

33 Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997; 389:856–860.

34 Fumagalli F, Di Pasqua L, Caffino L, Racagni G, Riva MA. Repeated exposure to cocaine differentially modulates BDNF mRNA and protein levels in rat striatum and prefrontal cortex. Eur J Neurosci 2007; 26:2756–2763.

35 Filip M, Faron-Gorecka A, Kusmider M, Golda A, Frankowska M, Dzedzicka-Wasyleswka M. Alterations in BDNF and trkB mRNAs following acute and chronic cocaine treatments and withdrawal. Brain Res 2006; 1071:218–225.

36 Miller MW, Mooney SM. Chronic exposure to ethanol alters neurotrophin content in the basolateral-accumbens system in the mature rat: effects on autocrine-paracrine mechanisms. J Neurobiol 2004; 60:490–498.